GSK pays $70M to extend its entry to Tempus affected person information library


Share post:

British multinational pharmaceutical and biotech firm GSK introduced a three-year settlement with a $70 million preliminary fee to broaden its entry to Tempus’ AI-powered information library, together with its de-identified affected person information. 

GSK says the collaboration will permit it to leverage the U.S.-based firm’s library to speed up drug discovery in oncology, enhance its scientific trial design, establish drug targets and velocity up trial enrollment. 

After three years, GSK has the choice to increase the settlement for an extra two years.  

The collaboration builds on GSK and Tempus‘ present partnership targeted on scientific trial enrollment of sufferers with particular most cancers sorts, permitting GSK to entry Tempus’ de-identified affected person information particularly. 

The businesses are at the moment collaborating on an open-label section II research, utilizing a data-driven strategy designed to hurry up research timelines. 

“This collaboration will present GSK with distinctive insights to find higher medicines and rework drug discovery. Tempus enhances the work our staff is already doing on the intersection of genomics and machine studying throughout each early discovery and scientific trials,” Tony Wooden, chief scientific officer at GSK, mentioned in an announcement.


GSK has partnered with quite a few corporations up to now yr to spice up its scientific analysis capabilities.   

In April of this yr, GSK introduced a multiyear drug discovery partnership with AI-enabled pathology firm PathAI to advance scientific trials and drug improvement in oncology and for nonalcoholic steatohepatitis (NASH). 

Earlier this yr, GSK introduced it prolonged its drug discovery partnership with client genetics firm 23andMe till July 2023. That collaboration started in 2018 when GSK supplied $300 million to the now publicly traded firm.

Final yr, GSK expanded its partnership with Viome Life Sciences, a maker of at-home exams for intestine and immune system well being. The alliance permits GSK to check the connection between the intestine microbiome and a few power illnesses, like autoimmune problems.

Supply hyperlink


Please enter your comment!
Please enter your name here


Related articles